Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSCW) Research & Development (2020 - 2025)

Historic Research & Development for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to $3.0 million.

  • Ensysce Biosciences' Research & Development rose 7477.7% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 8703.2%. This contributed to the annual value of $7.2 million for FY2024, which is 485.06% down from last year.
  • Latest data reveals that Ensysce Biosciences reported Research & Development of $3.0 million as of Q3 2025, which was up 7477.7% from $1.9 million recorded in Q2 2025.
  • Ensysce Biosciences' 5-year Research & Development high stood at $6.4 million for Q4 2022, and its period low was $284378.0 during Q1 2021.
  • For the 5-year period, Ensysce Biosciences' Research & Development averaged around $2.4 million, with its median value being $1.9 million (2023).
  • Per our database at Business Quant, Ensysce Biosciences' Research & Development surged by 104660.62% in 2022 and then crashed by 6905.23% in 2023.
  • Quarter analysis of 5 years shows Ensysce Biosciences' Research & Development stood at $2.2 million in 2021, then surged by 194.44% to $6.4 million in 2022, then plummeted by 65.34% to $2.2 million in 2023, then soared by 70.31% to $3.8 million in 2024, then dropped by 22.29% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $1.9 million for Q2 2025, and $1.9 million during Q1 2025.